NCT06235437View on ClinicalTrials.gov

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141

PHASE1RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 29, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2027

Conditions
Metastatic Solid Tumor
Interventions
BIOLOGICAL

ASD141

Subjects will receive one of 4 dose levels of ASD141.

Trial Locations (2)

110

RECRUITING

Taipei Medical University Hospital, Taipei

704

RECRUITING

National Cheng Kung University Hospital, Tainan City

Sponsors
All Listed Sponsors
lead

Ascendo Biotechnology Co., Ltd.

INDUSTRY

NCT06235437 - Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141 | Biotech Hunter | Biotech Hunter